Dlin-MC3-DMA: Gold Standard Ionizable Lipid for LNP siRNA & mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid engineered for robust siRNA and mRNA delivery in lipid nanoparticles (LNPs) (Wang et al., 2022). It achieves endosomal escape via pH-dependent charge switching, significantly enhancing cytoplasmic nucleic acid release (Lab Delivery Guide, 2023). Comparative studies show Dlin-MC3-DMA delivers around 1000-fold greater potency in hepatic gene silencing relative to its precursor (Wang et al., 2022). Dlin-MC3-DMA underpins several clinically validated LNP mRNA vaccine and siRNA drug platforms, including those for COVID-19 (Wang et al., 2022). Solutions must be prepared fresh and handled under cold conditions to preserve efficacy (APExBIO).

Biological Rationale

Dlin-MC3-DMA is designed as an ionizable cationic lipid to address the major challenge of delivering nucleic acids (siRNA, mRNA) across cellular membranes. The negative charge of nucleic acids impedes passive diffusion. Lipid nanoparticles (LNPs) leverage Dlin-MC3-DMA to encapsulate these molecules and facilitate cellular uptake. Ionizable amino lipids remain neutral at physiological pH (7.4), minimizing systemic toxicity, but become protonated in the acidic endosomal environment (pH ~5.5), which is crucial for endosomal escape. This charge-switching property is essential for the cytoplasmic release of the nucleic acid payload. Dlin-MC3-DMA has been shown to outperform other lipid scaffolds in both potency and tolerability (Wang et al., 2022). Its structure and function have been optimized through iterative design and machine learning-guided approaches.

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Upon formulation with helper lipids (DSPC), cholesterol, and PEGylated lipids (e.g., PEG-DMG), Dlin-MC3-DMA assembles into lipid nanoparticles capable of encapsulating siRNA or mRNA. At physiological pH, Dlin-MC3-DMA is largely uncharged, minimizing interactions with serum proteins and reducing off-target effects. Following cellular uptake via endocytosis, the acidic endosomal environment protonates the dimethylamino group, rendering the lipid positively charged. This cationic state promotes membrane fusion and destabilization, facilitating endosomal escape and cytoplasmic delivery of the nucleic acid payload. The efficiency of this escape mechanism is critical for effective gene silencing or protein expression. Dlin-MC3-DMA's molecular structure, including its (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate backbone, is key to its performance in nucleic acid delivery systems (APExBIO).

Evidence & Benchmarks

• DLin-MC3-DMA-based LNPs (N/P ratio 6:1) induce higher mRNA delivery efficiency in mice than SM-102, as validated by both machine learning prediction and in vivo experiments (Wang et al., 2022, DOI).
• Dlin-MC3-DMA achieves an ED50 of 0.005 mg/kg in mice and 0.03 mg/kg in non-human primates for transthyretin (TTR) gene silencing—approximately 1000-fold more potent than DLin-DMA (Jayaprakash et al., 2014, DOI).
• LNPs incorporating Dlin-MC3-DMA enable robust endosomal escape, as visualized by molecular modeling and dynamic simulation (Wang et al., 2022, DOI).
• Dlin-MC3-DMA is insoluble in water and DMSO but soluble in ethanol at ≥152.6 mg/mL, ensuring compatibility with standard lipid formulation workflows (APExBIO).
• DLin-MC3-DMA is a critical component of LNPs used in approved mRNA vaccines (e.g., Comirnaty/BNT162b2) and advanced siRNA therapeutics (Wang et al., 2022, DOI).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is widely applied in:

• Lipid nanoparticle siRNA delivery for hepatic gene silencing (Factor VII, TTR).
• mRNA vaccine formulation for infectious disease and cancer immunochemotherapy.
• In vivo gene silencing and immunomodulatory drug delivery studies.

Key limits and misconceptions:

Common Pitfalls or Misconceptions

• Dlin-MC3-DMA is not water-soluble; improper solvent use leads to aggregation and poor encapsulation efficiency.
• It is not suitable for direct in vivo injection without formulation into LNPs; free lipid is toxic.
• The neutral charge at physiological pH does not equate to zero off-target effects; formulation and dosing must be optimized.
• LNPs with Dlin-MC3-DMA are not universally ideal for all cell types; tissue tropism depends on helper lipid composition and surface modifications.
• Long-term storage of Dlin-MC3-DMA solutions at room temperature results in hydrolysis and potency loss; cold storage is mandatory.

This article extends the practical workflow tips from Solving Real-World mRNA & siRNA Delivery Challenges by providing mechanistic and benchmark data, and it updates Mechanistic Insights and Strategic Horizons with machine learning–validated findings for translational researchers.

Workflow Integration & Parameters

Dlin-MC3-DMA (A8791, APExBIO) is formulated with DSPC, cholesterol, and PEG-DMG to prepare LNPs using microfluidic mixing or ethanol injection methods. The recommended storage is at –20°C or below. Lipid stocks should be freshly prepared in ethanol, and LNPs should be used within hours to avoid hydrolysis. The optimal N/P ratio (nitrogen of lipid to phosphate of nucleic acid) is typically 6:1 for mRNA and siRNA delivery. LNPs are characterized by dynamic light scattering for size (typically 80–120 nm) and encapsulation efficiency (>90%). For hepatic gene silencing, dosing is performed intravenously at 0.005–0.03 mg/kg for mouse/primate models. Dlin-MC3-DMA is compatible with high-throughput screening and machine learning–guided optimization platforms (Wang et al., 2022). For further workflow optimization, see the comparative guide Dlin-MC3-DMA: Ionizable Cationic Liposome for mRNA & siRNA Delivery, which this article updates by providing newer benchmarking and parameterization details.

Conclusion & Outlook

Dlin-MC3-DMA is a validated, high-potency, and broadly adopted ionizable cationic liposome lipid for LNP-based siRNA and mRNA drug delivery. It has set the standard for in vivo hepatic gene silencing and mRNA vaccine development. Machine learning–guided optimization and advanced molecular modeling continue to refine its use and extend its applications in cancer immunochemotherapy and beyond. APExBIO provides Dlin-MC3-DMA (SKU A8791) with rigorous quality standards for research and translational workflows. As the field advances, Dlin-MC3-DMA is expected to remain foundational in next-generation LNP technologies, though proper formulation, storage, and workflow integration are vital for optimal performance.